Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Janux Therapeutics (NASDAQ:JANX) released its quarterly earnings results on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10), FiscalAI reports. The company had revenue of $10.27 million for the quarter, compared to the consensus estimate of $19.07 million.

Janux Therapeutics Stock Down 1.6%

JANX traded down $0.25 during mid-day trading on Friday, reaching $15.85. 689,025 shares of the company traded hands, compared to its average volume of 744,057. The stock has a market capitalization of $966.53 million, a P/E ratio of -9.66 and a beta of 2.50. Janux Therapeutics has a 52-week low of $12.12 and a 52-week high of $35.34. The company’s fifty day moving average price is $15.04 and its 200-day moving average price is $14.44.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, VP Maria Dobek sold 2,038 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares in the company, valued at approximately $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares in the company, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. raised its position in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after buying an additional 2,502 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Janux Therapeutics by 185.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock worth $177,000 after buying an additional 4,982 shares during the period. AQR Capital Management LLC lifted its position in shares of Janux Therapeutics by 71.7% in the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock valued at $262,000 after acquiring an additional 4,059 shares in the last quarter. Finally, Jain Global LLC bought a new position in shares of Janux Therapeutics in the third quarter worth about $241,000. 75.39% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on JANX. Evercore set a $22.00 price objective on Janux Therapeutics in a research report on Monday, May 11th. UBS Group lowered Janux Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $57.00 to $15.00 in a research report on Wednesday, April 15th. Barclays cut Janux Therapeutics from an “overweight” rating to an “underweight” rating and lowered their price objective for the company from $29.00 to $14.00 in a research note on Monday, April 20th. Wedbush lowered their price target on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, May 8th. Finally, Stifel Nicolaus set a $35.00 price target on shares of Janux Therapeutics in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.58.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.